These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25628944)

  • 1. Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.
    Sperr WR; Pfeiffer T; Hoermann G; Herndlhofer S; Sillaber C; Mannhalter C; Kundi M; Valent P
    Am J Cancer Res; 2015; 5(1):354-62. PubMed ID: 25628944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
    Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The underestimated role of basophils in Ph
    Valent P; Horny HP; Arock M
    Eur J Clin Invest; 2018 Oct; 48(10):e13000. PubMed ID: 30019447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph
    Sadovnik I; Ivanov D; Smiljkovic D; Stefanzl G; Degenfeld-Schonburg L; Herndlhofer S; Eisenwort G; Hauswirth AW; Sliwa T; Keil F; Sperr WR; Valent P
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tryptase Positivity in Chronic Myeloid Leukemia With Marked Basophilia.
    Khafateh Y; Aqil B
    Cureus; 2020 Aug; 12(8):e9577. PubMed ID: 32913693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
    Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
    Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
    Xia L; Qian W; Yang M; Li Q; Liu F; Xie Y
    Onco Targets Ther; 2015; 8():2485-92. PubMed ID: 26392775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.
    Drummond M; Lennard A; Brûmmendorf T; Holyoake T
    Leuk Lymphoma; 2004 Sep; 45(9):1775-81. PubMed ID: 15223635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7.
    Agis H; Krauth MT; Mosberger I; Müllauer L; Simonitsch-Klupp I; Schwartz LB; Printz D; Böhm A; Fritsch G; Horny HP; Valent P
    J Clin Pathol; 2006 Apr; 59(4):396-402. PubMed ID: 16461568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications].
    Tian J; Cheng H; Xu KL; Pan XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1056-60. PubMed ID: 19698259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
    Söderlund S; Dahlén T; Sandin F; Olsson-Strömberg U; Creignou M; Dreimane A; Lübking A; Markevärn B; Själander A; Wadenvik H; Stenke L; Richter J; Höglund M
    Eur J Haematol; 2017 Jan; 98(1):57-66. PubMed ID: 27428357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.